DYRK1A/B Inhibitor AnnH31

AdipoGen Life Sciences
Product Code: AG-CR1-3650

CodeSizePrice
AG-CR1-3650-C500500 ug£140.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
-20°C
Storage:
Short Term: +4°C. Long Term: -20°C

Images

1 / 1
Chemical Structure

Chemical Structure

Further Information

Alternate Names/Synonyms:
2-(7-Methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)acetonitrile; AnnH31
Appearance:
Off-white to tan solid.
CAS:
241809-12-1
EClass:
32160000
Form (Short):
solid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.Protect from light and moisture.
Hazards:
H319
InChi:
InChI=1S/C15H13N3O/c1-10-15-13(5-7-17-10)12-4-3-11(19-2)9-14(12)18(15)8-6-16/h3-5,7,9H,8H2,1-2H3
InChiKey:
FCFDJQKAPLIDTQ-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 241809-12-1. Formula: C15H13N3O. MW: 251.3. Synthetic. Potent selective membrane-permeable DYRK1A (IC50=81nM) and DYRK1B inhibitor. Off-target inhibition of CLK1 and slightly DYRK2 and HIPK2. Shows minimal inhibitory effects on monoamine oxidase A (MAO A) (IC50=3.2µg), with 40-fold selectivity for DYRK1A over MAO A. Dose-dependently reduced the phosphorylation of three known DYRK1A substrates (SF3B1, SEPT4 and tau) without negative effects on cell viability in celular assays. Shows cytotoxic effects in HeLa cells at high concentrations (3-10µM). The pleiotropic protein kinase DYRK1A has diverse functions in cell cycle control, neuronal differentiation and synaptic transmission and has attracted increasing interest as a potential drug target, due to its role in the pathology of Down syndrome, neurodegenerative diseases such as Alzheimer's disease and cancer. The closely related kinase DYRK1B has been associated with cancer cell survival by arresting cells in a quiescent state to allow cellular repair and mutations in DYRK1B might be causative in metabolic syndrome.
MDL:
N/A
Molecular Formula:
C15H13N3O
Molecular Weight:
251.3
Other data:
DMSO Stock Solution: Prior to performing biological experiments the DMSO stock solution should be further diluted into water or other aqueous buffers to ensure that the residual amount of DMSO is insignificant, since DMSO may have physiological effects at high concentrations.
Package Type:
Plastic Vial
Precautions:
P305, P351, P338
Product Description:
Potent selective membrane-permeable DYRK1A (IC50=81nM) and DYRK1B inhibitor. Off-target inhibition of CLK1 and slightly DYRK2 and HIPK2. Shows minimal inhibitory effects on monoamine oxidase A (MAO A) (IC50=3.2µg), with 40-fold selectivity for DYRK1A over MAO A. Dose-dependently reduced the phosphorylation of three known DYRK1A substrates (SF3B1, SEPT4 and tau) without negative effects on cell viability in celular assays. Shows cytotoxic effects in HeLa cells at high concentrations (3-10µM). The pleiotropic protein kinase DYRK1A has diverse functions in cell cycle control, neuronal differentiation and synaptic transmission and has attracted increasing interest as a potential drug target, due to its role in the pathology of Down syndrome, neurodegenerative diseases such as Alzheimer's disease and cancer. The closely related kinase DYRK1B has been associated with cancer cell survival by arresting cells in a quiescent state to allow cellular repair and mutations in DYRK1B might be causative in metabolic syndrome.
Purity:
>98% (HPLC, NMR)
Signal Word:
Warning
SMILES:
CC1=NC=CC2=C1N(CC#N)C3=CC(OC)=CC=C32
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.

References

Selectivity profiling and biological activity of novel beta-carbolines as potent and selective DYRK1 kinase inhibitors: K. Ruben, et al.; PLos One 10, e0132453 (2015)